STOCKHOLM, June 15, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced the
appointment of Marie Svensson as
Chief Financial Officer, CFO. Marie
Svensson has more than 20 years of experience from various
financial positions in the high-tech industry and will be a member
of Alligator's executive management team.
Marie Svensson joins Alligator
from her recent position as CFO at InCoax Networks, a developer of
innovative broadband solutions. Prior to that Marie was Director of
Finance at Sol Voltaics AB, a development company within
nanotechnology for solar cells. Marie has a Bachelor of Science in
accounting and a Master of Business Administration/Management from
Lund University.
"Marie Svensson brings a
broad experience including product management, business
controlling, financial management and corporate governance with a
focus on rapid-growing early stage companies. It is with great
pleasure I welcome Marie to our team," said Per Norlén, CEO
of Alligator Bioscience.
"I have been attracted to Alligator, partly because I like
working with dedicated people in an innovative environment. But
what is even more exciting is the company's potential to develop
effective therapies for patients in need", said Marie Svensson.
Marie Svensson will start her
position on September 1, 2020. In the
meantime, Andreas Johannesson will
continue his role as interim CFO.
The information was submitted for publication, through the
agency of the contact person set out above, at 11:00 a.m. CEST
on June 15, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes five lead clinical and preclinical
drug candidates: Mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527
(co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical
development by Shanghai Henlius Biotech Inc.). Alligator's shares
are listed on Nasdaq Stockholm (ATORX). The Company is
headquartered in Lund, Sweden. For
more information, please visit www.alligatorbioscience.com.
For further information, please contact:
Cecilia Hofvander
Director Investor Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-appoints-new-cfo,c3134363
The following files are available for download:
https://mb.cision.com/Main/12681/3134363/1264282.pdf
|
Alligator Bioscience
appoints new CFO
|